Abstract
Progress in the field of NK cell receptors (NKRs) and their ligands has revolutionized our concept of how NK cells selectively recognize and lyse tumor while sparing normal cells. Major families of NKRs that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulin-like receptors (KIRs), C-type lectins, and natural cytotoxicity receptors. Identification of NK receptor ligands such as HLA, MHC class I chain-related genes A and B – MICA/B, etc. further clarifies the role of NKR/ligand interactions in NK cell function. Given the extensive genomic diversity of KIRs, HLA and MIC, it is reasonable to imagine that genotypes encoding imbalanced inhibitory and activating interactions may contribute to susceptibility or resistance to human diseases, including cancers. This review will discuss two cell-surface receptor/ligand systems involved in NK cell recognition of tumor targets – KIR/HLA and NKG2D/MIC and the potential relevance of their genetic polymorphism in malignancies.
Keywords: NK cell receptors, NK receptor ligands, polymorphism, malignancies
Current Cancer Therapy Reviews
Title: NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Volume: 4 Issue: 2
Author(s): Anastassia Mihaylova, Snejina Mihailova and Elissaveta Naumova
Affiliation:
Keywords: NK cell receptors, NK receptor ligands, polymorphism, malignancies
Abstract: Progress in the field of NK cell receptors (NKRs) and their ligands has revolutionized our concept of how NK cells selectively recognize and lyse tumor while sparing normal cells. Major families of NKRs that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulin-like receptors (KIRs), C-type lectins, and natural cytotoxicity receptors. Identification of NK receptor ligands such as HLA, MHC class I chain-related genes A and B – MICA/B, etc. further clarifies the role of NKR/ligand interactions in NK cell function. Given the extensive genomic diversity of KIRs, HLA and MIC, it is reasonable to imagine that genotypes encoding imbalanced inhibitory and activating interactions may contribute to susceptibility or resistance to human diseases, including cancers. This review will discuss two cell-surface receptor/ligand systems involved in NK cell recognition of tumor targets – KIR/HLA and NKG2D/MIC and the potential relevance of their genetic polymorphism in malignancies.
Export Options
About this article
Cite this article as:
Mihaylova Anastassia, Mihailova Snejina and Naumova Elissaveta, NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310070
DOI https://dx.doi.org/10.2174/157339408784310070 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets A Unique Intracellular, Extracellular and Transmembrane Circulation of Potassium Ions in the Auditory Inner Ear as an Anticarcinogenic Principle? Part 1
Inflammation & Allergy - Drug Targets (Discontinued) Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling
Current Genomics Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets HPV-mediated Cervical Cancer: A Systematic Review on Immunological Basis, Molecular Biology, and Immune Evasion Mechanisms
Current Drug Targets Mevalonate Cascade and Small Rho GTPase in Spinal Cord Injury
Current Molecular Pharmacology Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Current Molecular Medicine Antiproliferative and Pro-Apoptotic Effects of Thiazolo[3,2–b][1,2,4]triazoles in Breast and Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science Assessment of Ploy Dopamine Coated Fe<sub>3</sub>O<sub>4</sub> Nanoparticles for Melanoma (B16-F10 and A-375) Cells Detection
Anti-Cancer Agents in Medicinal Chemistry Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design A Qualitative and Quantitative Study of the Innervation of the Human Non Pregnant Uterus
Current Protein & Peptide Science Cell-based Therapy for Ocular Disorders: A Promising Frontier
Current Stem Cell Research & Therapy Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology Insights into the Dynamic Fluctuations of the Protein HPV16 E1 and Identification of Motifs by Using Elastic Network Modeling
Protein & Peptide Letters Effectiveness of Hsp90 Inhibitors as Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets Key Roles of MicroRNA-22 Family in Complex Organisms Inferred from its Evolution
MicroRNA